Balyasny Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.16M | Sell |
68,869
-198,273
| -74% | -$6.21M | ﹤0.01% | 1144 |
|
|
2025
Q1 | $8.96M | Buy |
267,142
+82,562
| +45% | +$2.77M | 0.01% | 689 |
|
|
2024
Q4 | $7.24M | Buy |
184,580
+100,382
| +119% | +$3.93M | 0.01% | 753 |
|
|
2024
Q3 | $3.31M | Sell |
84,198
-149,137
| -64% | -$5.87M | 0.01% | 974 |
|
|
2024
Q2 | $9.1M | Buy |
233,335
+32,061
| +16% | +$1.25M | 0.02% | 666 |
|
|
2024
Q1 | $8.66M | Buy |
201,274
+185,423
| +1,170% | +$7.98M | 0.02% | 727 |
|
|
2023
Q4 | $730K | Buy |
+15,851
| New | +$730K | ﹤0.01% | 1304 |
|
|
2023
Q1 | – | Sell |
-162,828
| Closed | -$6.42M | – | 2699 |
|
|
2022
Q4 | $6.42M | Buy |
162,828
+15,473
| +11% | +$610K | 0.02% | 689 |
|
|
2022
Q3 | $5.32M | Buy |
+147,355
| New | +$5.32M | 0.02% | 734 |
|